Audeo Oncology postpones $49 million IPO

By Renaissance Capital,

Shutterstock photo

Audeo Oncology, which is developing a combination therapy in Phase 3 trial for metastatic colorectal cancer, postponed its IPO on Thursday, citing poor market conditions. The San Francisco, CA-based company was founded in 2006 and has yet to generate product revenue. Leerink Swann and Oppenheimer & Co. were set to be the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: AURX

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by